Class of Stock [Axis]
Series L Preferred Stock [Member]
Series C Preferred Stock [Member]
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Mezzanine Equity [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Purchase Agreement [Member]
Inducement Warrants [Member]
Series A Inducement Warrants [Member]
Series B Inducement Warrants [Member]
Debt Instrument [Axis]
May 2025 Private Placement [Member]
Class of Warrant or Right [Axis]
Warrants [Member]
Securities Purchase Agreement [Member]
Series L 10% Convertible Preferred Stock [Member]
Common Warrants [Member]
Vesting Warrants [Member]
Greenshoe Rights [Member]
Award Type [Axis]
2022 Omnibus Incentive Plan [Member]
Statistical Measurement [Axis]
Maximum [Member]
Exercise Price Range [Axis]
Range of Exercise Price One [Member]
Range of Exercise Price Two [Member]
Range of Exercise Price Three [Member]
Range of Exercise Price Four [Member]
Range of Exercise Price Five [Member]
Range of Exercise Price Six [Member]
Range of Exercise Price Seven [Member]
Range of Exercise Price Eight [Member]
Range of Exercise Price Nine [Member]
Range of Exercise Price Ten [Member]
Litigation Case [Axis]
Z-One, LLC [Member]
Coby Silberfein [Member]
Justin DiPietro [Member]
Phillip Werthman Trust [Member]
2023 Sponsored Research Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
2016 Exclusive Patent License Agreement [Member]
Award Date [Axis]
2017 through 2020 [Member]
Minimum [Member]
Beginning in 2022 [Member]
Beginning in 2025 [Member]
Beginning in 2027 [Member]
Beginning in 2026 [Member]
2021 Exclusive License Agreement [Member]
2021 Exclusive License Agreement [Member]
2024 GTB-3650 Clinical Trial Agreement [Member]
2026 GTB-5550 Clinical Trial Agreement [Member]
Advisory Agreement [Member]
Amended Advisory Agreement [Member]
Segments [Axis]
Clinical Stage Biopharmaceutical Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement [Table]
Statement [Line Items]
ASSETS
Current assets
Cash and cash equivalents
Restricted cash
Deferred offering costs
Prepaid expenses and other current assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable
Accrued expenses
Warrant liability
Total Current Liabilities
Stockholders’ Equity
Preferred stock value
Common stock, par value $0.001, 250,000,000 shares authorized, 44,668,969 and 25,534,173 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid in capital
Accumulated deficit
Total Stockholders’ Equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Operating Expenses:
Research and development
Selling, general and administrative
Loss from Operations
Other Income (Expense)
Interest income
Interest expense
Loss on initial recognition of Greenshoe Rights liability
Change in fair value of warrant liability
Gain on settlement of vendor payable
Other income
Total Other Income (Expense), net
Net Loss
Dividend on preferred stock
Deemed dividend
Net Loss attributable to common stockholders’
Net Loss Per Share - Basic
Net Loss Per Share - Diluted
Weighted average common shares outstanding - basic
Weighted average common shares outstanding - diluted
Balance
Balance, shares
Mezzanine equity balance, shares
Mezzanine equity balance
Exercise of warrants for cash, net
Exercise of warrants for cash, net, shares
Issuance of prefunded warrants for services
Series L convertible preferred stock and warrants issued for cash, net
Series L convertible preferred stock and warrants issued for cash, net, shares
Conversion of Series L convertible preferred stock into common stock
Conversion of Series L convertible preferred stock into common stock, shares
Dividend on Series L convertible preferred stock
Dividend on Series L convertible preferred stock, shares
Fair value of vested stock options
Net loss
Exercise of warrants for cash and inducement warrants, net
Exercise of warrants for cash and inducement warrants, net, shares
Issuance and exercise of prefunded warrants for ELOC fee
Issuance and exercise of prefunded warrants for ELOC fee, shares
Issuance of common stock and warrants for services
Issuance of common stock and warrants for services, shares
Issuance of warrants for VRT waiver
Issuance of prefunded warrants in settlement of vendor payable
Balance
Balance, shares
Mezzanine equity balance, shares
Mezzanine equity balance
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to reconcile net loss to net cash used in operating activities:
Fair value of vested stock options
Issuance of warrants for VRT waiver
Loss on initial recognition of Greenshoe Rights liability
Change in fair value of warrant liability
Gain on settlement of debt
Gain on extinguishment of debt
Changes in operating assets and liabilities:
(Increase) Decrease in prepaid expenses
Increase (Decrease) in accounts payable and accrued expenses
Net Cash Used in Operating Activities
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Exercise of warrants for cash, net
Proceeds from issuance of Series L convertible preferred stock and warrants, net
Net Cash Provided by Financing Activities
Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents and Restricted Cash at Beginning of Period
Cash and Cash Equivalents and Restricted Cash at End of Period
Cash paid during the period for:
Interest
Income taxes
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of vested warrants issued in Series L conv. preferred stock transaction
Fair value of prefunded warrants issued for ELOC fee
Fair value of common stock and warrants issued for services
Fair value of prefunded warrants and common stock to settle vendor payable
Conversion of Series L convertible preferred stock into common stock
Dividend on Series L convertible preferred stock
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Going Concern Analysis
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Equity [Abstract]
Stockholders’ Equity (Deficit)
Common Stock Warrants And Options
Common Stock Warrants and Options
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Accounting Estimates
Cash Equivalents
Restricted Cash
Deferred Offering Costs
Stock-Based Compensation
Research and Development Expenses
Net Loss Per Share
Concentration
Segment Information
Recent Accounting Pronouncements
Schedule of Anti-dilutive Securities
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Schedule of Common Stock Warrant Transactions
Schedule of Warrants Exercisable
Schedule of Options Activity
Schedule of Options Outstanding and Options Exercisable
Schedule of Segment Information
Net loss
Net cash used in operating activities
SummaryOfSignificantAccountingPoliciesDetailsNarrativeTable [Table]
SummaryOfSignificantAccountingPoliciesDetailsNarrativeLineItems [Line Items]
Cash equivalents
Preferred stock dividends
Cash, FDIC insured amount
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities
Conversion price per share
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purcahse
Weighted average volume price of common stock percentage
Placement agents
Proceeds from private placement
Other offering expenses
Issuance of warrants, exercisable
Share price
Exercise price
Warrant term
Equity issuance cost
Shares issued
Aggregate stated value
Proceeds from issuance of preferred stock
Conversion price
Deemed dividend
Dividend amount
Shares issued for dividends
Schedule Of Common Stock Warrant Transactions
Warrants outstanding, beginning balance
Weighted average exercise price, beginning balance
Number of warrants, granted
Weighted average exercise price, granted
Number of warrants, anti-dilution adjustment
Weighted average exercise price, anti-dilution adjustment
Number of warrants, forfeited/cancelled
Weighted average exercise price, forfeited/cancelled
Number of warrants, exercised
Weighted average exercise price, exercised
Warrants outstanding, ending balance
Weighted average exercise price, ending balance
Warrants exercisable, ending balance
Weighted average exercise price, exercisable, ending balance
Range of exercise price
Number of outstanding
Warrants weighted average exercise price
Warrants outstanding, weighted average remaining contractual life (years)
Schedule Of Options Activity
Number of options outstanding, beginning
Weighted-average exercise price, beginning
Number of options, granted
Weighted-average exercise price, granted
Number of options, forfeited/cancelled
Weighted-average exercise price, forfeited/cancelled
Number of options, exercised
Weighted-average exercise price, exercised
Number of options outstanding, ending
Weighted-average exercise price, ending
Number of options outstanding exercisable
Weighted-average exercise price, exercisable, ending
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of excercise price
Number outstanding
Weighted average remaining contractual life (years)
Weighted average exercise price
DisclosureCommonStockWarrantsAndOptionsTable [Table]
Options outstanding intrinsic value
Options outstanding intrinsic value vested and exercisable
Vesting warrants
Exercise price per share
Warrants rights outstanding
Floor price
Shares of common stock
Vendor as compensation for services
Common stock awards granted
Stock option outstanding
Rstricted stock granted
Granted, shares
Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term
Options outstanding intrinsic value
Stock option, exercisable
Stock option, unvested compensation
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Principal amount
Damages sought value
Loss contingency, owes damages
Aggregate research and development expense
Payments of research and development
Research and development expense
Outstanding commitments
Proceeds from upfront amount
License maintenance fees
Royalty fee percentage
Annual royalty payments
Performance milestone payments
One-time sales milestone payments
Gross sales
Sales revenue
Cumulative gross sales
Royalty expense year one
Royalty expense years two through five
Royalty expense year six and thereafter
Upfront license fee
Royalty expense year one though four
Royalty expense year five and thereafter
Unbilled and unaccrued amounts
Cash payment
Pre-funded warrant to purchase shares of common stock
Stock issuance
Minimum bid price requirement description
Share Price
Segment Reporting [Table]
Segment Reporting [Line Items]
Research and development
Salaries
Insurance
Stock-based compensation
Operating expenses
Loss on initial recognition of Greenshoe Rights liability
Other expense (income)
Net loss
Number of reportable segments
Number of operating segments
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of converted shares
Preferred stock conversion shares
Warrant liability current.
Series L Preferred Stock [Member]
Loss on initial recognition of greenshoe rights liability.
Stock issued during period value exercise of warrants for cash net.
Stock issued during period shares exercise of warrants for cash net.
Dividends preferred stock shares.
Exercise of warrants for cash and inducement warrants, net, value.
Exercise of warrants for cash and inducement warrants, net, shares.
Issuance of prefunded warrant to settle vendor payable, value.
Stock issued during period value issuance and exercise of prefunded warrants for eloc fee
Issuance and exercise of prefunded warrants for ELOC fee, shares.
Mezzanine Equity [Member]
Fair value of vested warrants issued in seriesL convertible preferred stock transaction.
Fair value of prefunded warrant and common stock to settle vendor payable.
Fair value of prefunded warrants issued for eloc fee
Issuance of warrants for vrt waiver.
Gain on settlement of debt.
Purchase Agreement [Member]
Weighted average volume price of common stock percentage.
Share based compensation arrangement by share based payment award non options exercisable number.
Inducement Warrants [Member]
Series A Inducement Warrants [Member]
Series B Inducement Warrants [Member]
May 2025 Private Placement [Member]
Stock issued during period shares dividends.
Common Stock Warrants and Options [Text Block]
Granted pursuant to full ratchet price protection, shares.
Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.
Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non options granted weighted average exercise price.
Granted pursuant to full ratchet price protection, weighted average exercise price.
Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.
Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.
Securities Purchase Agreement [Member]
Series L 10% Convertible Preferred Stock [Member]
Common Warrants [Member]
Vesting Warrants [Member]
Greenshoe Rights [Member]
Schedule of Warrants Oustanding and Exercisable [Table Text Block]
Range of Exercise Price One [Member]
Range of Exercise Price Two [Member]
Range of Exercise Price Three [Member]
Range of Exercise Price Four [Member]
Range of Exercise Price Five [Member]
Range of Exercise Price Six [Member]
Range of Exercise Price Seven [Member]
Range of Exercise Price Eight [Member]
Range of Exercise Price Nine [Member]
Range of Exercise Price Ten [Member]
2022 Omnibus Incentive Plan [Member]
Share based compensation arrangement by share based payment award options non vested in period fair value 1.
Z-One, LLC [Member]
Coby Silberfein [Member]
2023 Sponsored Research Agreement [Member]
Outstanding commitments.
2016 Patent License Agreement [Member]
2017 through 2020 [Member]
Royalty fee percentage.
Received upfront payment.
Beginning in 2027 [Member]
Beginning in 2022 [Member]
Beginning in 2025 [Member]
Sales milestone payments.
Performance milestone payments.
Sales revenue.
Cummulative gross sales.
Gross sales.
Royalty expense year one.
Royalty expense year two through five.
Royalty expense year after six.
Upfront license fee.
2021 Patent License Agreement [Member]
Royalty expense year one though four.
Royalty expense year five and thereafter.
2024 GTB-3650 Clinical Trial Agreement [Member]
2026 GTB-5550 Clinical Trial Agreement [Member]
Advisory Agreement [Member]
Minimum bid price requirement description.
Amended Advisory Agreement [Member]
Series L 10% Convertible Preferred Stock [Member]
Preferred stock purchase price
Dividend on convertible preferred stock.
Warrants [Member]
2021 Exclusive License Agreement [Member]
Clinical Stage Biopharmaceutical Member]
Justin DiPietro [Member]
Phillip Werthman Trust [Member]
Beginning in 2026 [Member]
Fair value of vested stock options.
Loss on initial recognition of liability.
2021 Exclusive License Agreement [Member] [Default Label]
Assets, Current
Liabilities, Current
Equity, Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Net Income (Loss) Available to Common Stockholders, Basic
Shares, Outstanding
Temporary Equity, Shares Outstanding
Temporary Equity, Carrying Amount, Attributable to Parent
FairValueOfVestedStockOptions
IssuanceOfWarrantsForVrtWaiver
Gain (Loss) on Extinguishment of Debt
Increase (Decrease) in Prepaid Expense
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Proceeds from Warrant Exercises
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Conversion of Stock, Amount Issued
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Segment Reporting, Policy [Policy Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
Other Research and Development Expense
LossOnInitialRecognitionOfLiability